Go to the list of all blogs
Serhii Bondarenko's Avatar
published in Blogs
Jun 19, 2025

Analysis of Tilray Brands' (TLRY) Stock for June 2025: Market Trends and AI-Powered Perspectives

Tilray Brands, Inc. (Nasdaq: TLRY) is a global leader in the cannabis, beverage, and wellness industries, headquartered in New York and Leamington, Ontario. As a prominent player in the cannabis sector, Tilray has garnered significant investor attention due to its strategic expansions and market performance. This article provides a comprehensive financial analysis of TLRY as of June 19, 2025, incorporating recent market movements, statistical data, comparisons with correlated stocks and inverse ETFs, and the role of AI-driven tools like those offered by Tickeron.com. The analysis also explores how traders can leverage these tools to navigate TLRY’s volatility and optimize their strategies.

TLRY Stock Performance: Recent Trends and Statistics

Tilray Brands has experienced notable volatility in 2025, reflective of the broader cannabis industry and macroeconomic factors. As of June 11, 2025, TLRY closed at $0.42, marking a +2.37% increase from the prior trading day, according to Yahoo Finance. Over the past week, the stock saw a 4.82% price increase, coinciding with the company’s approval of a reverse stock split, which grants greater flexibility in its stock structure. This performance aligns with a positive market environment, as the S&P 500 and Nasdaq recorded gains amid favorable inflation data and U.S.-China trade developments.

Key Financial Metrics

  • Market Capitalization: As of June 2025, Tilray’s market cap stands at approximately $320 million, reflecting its position as a mid-cap stock in the cannabis sector.
  • Price-to-Sales Ratio: TLRY’s price-to-sales ratio is around 0.4x, indicating a potentially undervalued stock relative to its revenue generation.
  • Debt Reduction: In the fiscal quarter ending February 28, 2025, Tilray reduced its total debt by $76 million, achieving a net debt to trailing twelve-month Adjusted EBITDA ratio of less than 1.0x, signaling improved financial health.
  • Trading Volume: Over the five trading days ending June 10, 2025, TLRY’s average daily trading volume was approximately 1.2 million shares, indicating moderate liquidity for a stock in its sector.
  • Year-to-Date Performance: TLRY has faced challenges in 2025, with its stock price down approximately 65% from its January high of $1.20, as noted in posts on X.

Technical Indicators

TLRY’s MACD Histogram crosses above the signal line

The Moving Average Convergence Divergence (MACD) for TLRY turned positive on June 10, 2025. Looking at past instances where TLRY’s MACD turned positive, the stock continued to rise in 38 of 43 cases over the following month. The odds of a continued upward trend are 88%.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 62 cases where TLRY’s Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron’s analysis proposes that the odds of a continued upward trend are 87%.

Following a +3.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in 161 of 198 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

TLRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 17, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on TLRY as a result. In 68 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TLRY entered a downward trend on June 06, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Market News Impacting TLRY: June 19, 2025

The stock market on June 19, 2025, reflects a complex interplay of macroeconomic and geopolitical factors influencing TLRY’s performance. Key market news includes:

  • Geopolitical Tensions: Stocks experienced volatility earlier in the week due to escalating conflicts between Israel and Iran, which pushed energy prices higher and led to a market downturn on June 13. The S&P 500 fell 1.13% to 5,976.97, and the Nasdaq Composite dropped 1.30% to 19,406.83. This broader market decline likely pressured TLRY, given its sensitivity to market sentiment.
  • Federal Reserve Policy: Investors are closely monitoring the Federal Reserve’s two-day meeting, which began on June 17, for indications of interest rate decisions. Expectations of steady rates in 2025, despite cooling inflation, suggest a cautious market environment that could impact high-beta stocks like TLRY.
  • Sector-Specific Developments: The cannabis sector remains under scrutiny due to regulatory uncertainties. However, Tilray’s recent debt reduction and strategic focus on beverage and wellness products position it favorably for long-term growth, even amidst short-term market fluctuations.

Comparison with a Correlated Stock: Canopy Growth Corporation (CGC)

Tilray’s stock performance is closely correlated with other cannabis industry players, notably Canopy Growth Corporation (Nasdaq: CGC). Both companies operate in the global cannabis market and are influenced by similar regulatory and market dynamics. Over the past year, TLRY and CGC have shown a correlation coefficient of approximately 0.85, indicating strong alignment in price movements.

  • Recent Performance: As of June 2025, CGC has also faced significant declines, trading at around $0.65, down 70% year-to-date, mirroring TLRY’s challenges. However, CGC’s larger market cap ($600 million) and broader international presence give it a slightly different risk profile.
  • Key Differences: While Tilray has diversified into beverages and wellness, CGC focuses heavily on cannabis-based pharmaceuticals. This divergence could lead to varied responses to regulatory changes, such as potential U.S. federal legalization, which some X users speculate could drive TLRY to $1.20 or higher.
  • Trading Insights: Investors tracking TLRY and CGC can leverage Tickeron’s AI-driven analytics to compare real-time trends, identifying which stock may offer better upside based on technical indicators like moving average crossovers or relative strength index (RSI).

Leveraging Inverse ETFs for Trading TLRY

For traders seeking to hedge TLRY’s volatility, inverse ETFs like the ProShares Short S&P 500 (SH) offer an anti-correlated instrument. SH aims to deliver the daily inverse performance of the S&P 500, which indirectly anti-correlates with TLRY due to its inclusion in broader market indices. During TLRY’s 4.82% weekly gain in early June 2025, SH likely declined by a similar magnitude, reflecting its inverse relationship.

  • Strategic Advantage: Pairing TLRY with SH allows traders to mitigate losses during market downturns. For instance, if TLRY declines due to sector-specific headwinds, SH’s gains can offset losses, providing a balanced portfolio approach.
  • Risk Considerations: Inverse ETFs like SH are designed for short-term strategies due to daily rebalancing, which can lead to compounding losses in prolonged trends. Tickeron’s AI tools can help traders identify optimal entry and exit points for SH, ensuring precise hedging in TLRY’s volatile trajectory.

Tickeron’s AI Trading Agents: Enhancing TLRY Strategies

Tickeron, led by CEO Sergey Savastiouk, has transformed trading through its Financial Learning Models (FLMs), which integrate machine learning with technical analysis to deliver high-probability trade setups. For TLRY, Tickeron’s AI Trading Robots and Double Agents provide dual-perspective signals, capturing both bullish and bearish trends. For example, Tickeron’s platform identified a bullish moving average crossover for TLRY on May 15, 2025, signaling potential upside to $0.50. By pairing TLRY with inverse ETFs like SH, Tickeron’s Double Agents offer a hedged approach, achieving a +9.77% quarterly gain in a declining market. These tools, accessible at Tickeron’s bot-trading platform, empower traders to navigate TLRY’s volatility with precision, making them essential for both novice and experienced investors.

Conclusion

Tilray Brands (TLRY) remains a compelling yet volatile investment in the cannabis sector as of June 19, 2025. Its recent 4.82% weekly gain, debt reduction, and strategic approval of a reverse stock split signal potential for recovery, despite a challenging year-to-date performance. By comparing TLRY with correlated stocks like CGC and leveraging inverse ETFs like SH, investors can balance risk and reward. Tickeron’s AI-driven tools, with their advanced Financial Learning Models, provide real-time insights and hedging strategies, making them invaluable for navigating TLRY’s market movements. As macroeconomic and regulatory developments unfold, traders should remain vigilant, using platforms like Tickeron.com to stay ahead in this dynamic sector.

Disclaimers and Limitations

Related Ticker: TLRY, CGC

TLRY's RSI Indicator ascends from oversold territory

The RSI Indicator for TLRY moved out of oversold territory on July 02, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 46 similar instances when the indicator left oversold territory. In of the 46 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Moving Average Convergence Divergence (MACD) for TLRY just turned positive on July 02, 2026. Looking at past instances where TLRY's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in of 206 cases, the price rose further within the following month. The odds of a continued upward trend are .

TLRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for TLRY entered a downward trend on July 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.345) is normal, around the industry mean (39.849). P/E Ratio (0.000) is within average values for comparable stocks, (99.069). TLRY's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.687). TLRY has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.034). P/S Ratio (0.541) is also within normal values, averaging (114.720).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. TLRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 3.99B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -0%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 19%. CPHI experienced the highest price growth at 92%, while EVO experienced the biggest fall at -31%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 26%. For the same stocks of the Industry, the average monthly volume growth was -38% and the average quarterly volume growth was -3%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 66
Price Growth Rating: 57
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 4 (-100 ... +100)
View a ticker or compare two or three
TLRY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a holding company, whose subsidiaries engages in research, cultivation, processing and distribution of medical cannabis

Industry PharmaceuticalsGeneric

Profile
Details
Industry
Biotechnology
Address
265 Talbot Street West
Phone
+1 844 845-7291
Employees
1600
Web
https://www.tilray.com
Interact to see
Advertisement
Recent analyst upgrades from Piper Sandler and Morgan Stanley underscore improving valuation and renewed confidence in Motorola Solutions’ growth outlook. Third-quarter 2025 results exceeded expectations, with revenue increasing 7.8% year over year, driven by land mobile radio (LMR) and video security demand.
Hexcel Corporation (HXL), a leading supplier of advanced composite materials used across aerospace, defense, and industrial markets, has maintained steady momentum amid a shifting industry backdrop. Recent share performance reflects investor optimism around a gradual recovery in commercial aviation, balanced against concerns about production timing and cost pressures.
TSM’s upcoming earnings carry outsized importance for the semiconductor industry. As the world’s leading contract chip manufacturer, TSMC underpins AI innovation for customers such as Nvidia and Apple. Its results often serve as a bellwether for global chip demand, capacity constraints, and pricing trends.
Goldman Sachs (GS) is expected to report Q4 2025 EPS of $11.65 on revenue of $13.85 billion, reflecting steady results as investment banking activity continues to recover.
Citigroup (C) is expected to report Q4 2025 EPS of $1.58, representing a 17.9% year-over-year increase, with revenue projected at $20.95 billion, up 7%. Bank of America (BAC) consensus estimates call for Q4 EPS of $0.96, up from $0.82, on revenue of $27.74 billion, reflecting 9.45% growth. JPMorgan Chase (JPM) is forecast to deliver Q4 EPS of $4.86, a modest 0.95% increase, with revenue expected to rise 8.13% to $46.25 billion.
Wells Fargo (WFC) is expected to report Q4 2025 earnings on January 14, 2026, with consensus calling for EPS of $1.66, up 16.9% year over year, and revenue of approximately $21.66 billion, a 6.3% increase. Investor focus will center on net interest income stabilization, growth in fee-based businesses such as investment banking and mortgages, and credit provisioning in a lower-rate environment.
Wall Street expects Infosys Q3 FY2026 EPS of $0.20, based on estimates from eight analysts, with revenue forecast at ₹452.37 billion (approximately $5.45 billion), compiled from 33 analysts.
BitMine Immersion Technologies (BMNR) is set to report Q1 FY2026 earnings on January 16, 2026, with consensus estimates calling for EPS of $0.15 and revenue of approximately $79.3 million.
Bank of America (BAC) and Wells Fargo (WFC) will both report Q4 2025 earnings on January 14, 2026, creating a rare same-day, apples-to-apples comparison.
Citigroup (C) is set to report Q4 2025 earnings on January 14, 2026, making it the immediate catalyst in this comparison. HSBC Holdings (HSBC) will release its Full-Year 2025 results on February 25, 2026, positioning it as a medium-term earnings event.
Wells Fargo’s quarterly results carry broader significance because the bank serves as a key indicator of U.S. consumer and commercial banking conditions. Its earnings often influence sentiment toward the entire large-cap banking sector. After a stretch of improved market conditions and stronger capital markets activity, investors are looking for confirmation that profit momentum is sustainable rather than driven by a single favorable quarter.
Infosys (INFY) will report Q3 FY2026 results on January 14, 2026, making it the immediate catalyst in this comparison. Accenture (ACN) last reported Q1 FY2026 earnings on December 18, 2025, with its next update scheduled later in the fiscal quarter.
BMNR reported fiscal Q4 and full-year FY2025 results (ending August 31, 2025), with profitability heavily influenced by digital-asset accounting and treasury positioning. Full-year diluted EPS: $13.39; Net income attributable to common stockholders: $328.161 million.
M&T Bank (MTB) is expected to deliver Q4 2025 EPS of $4.44–$4.46, representing roughly 13% year-over-year growth, driven by improving net interest income as funding costs decline. PNC Financial Services Group (PNC) is projected to post Q4 EPS of $4.19–$4.23, supported by about 1.5% sequential NII growth from rate relief and steady loan demand. U.S. Bancorp (USB) is forecast to earn $1.19 per share, an 11.2% annual increase, with revenues estimated at $7.33 billion, up 5%.
Dash (DASH.X) has ignited the crypto market with a powerful mid-January 2026 breakout, rallying more than 125% in a single week and decisively outperforming fellow privacy coins such as Monero and Zcash. The surge was fueled by a sharp short squeeze that wiped out nearly $4.9 million in bearish positions, alongside a major catalyst: Dash’s integration with Alchemy Pay, enabling direct fiat purchases across 173 countries.
As 2026 gets underway, ether.fi’s governance token (ETHFI.X) is emerging as a focal point for traders seeking exposure to Ethereum’s rapidly expanding liquid restaking ecosystem. With total value locked climbing to $7.8 billion, ether.fi now ranks as the second-largest staking protocol after Lido, underscoring its growing influence in the Ethereum economy.
The Schwab U.S. Small-Cap ETF (SCHA) is holding firm near the $28 level as 2026 begins, even as broader markets remain volatile. While short-term price action has been uneven, underlying signals suggest the ETF may be setting up for a meaningful breakout as interest-rate cuts revive small-cap equities. Technical models highlight an unusually favorable risk-reward profile—up to 22:1—with long-term momentum strengthening despite near-term consolidation.
The Vanguard Small-Cap Value ETF (VB) is quietly standing out in what has been a turbulent start to 2026. While many small-cap segments have struggled, VB has shown notable resilience, including a 3.2% jump on January 14, driven by renewed buying interest in undervalued industrial and financial stocks. This divergence from broader small-cap weakness suggests early signs of mean reversion, particularly as incoming economic data points toward eventual interest-rate relief.
The Vanguard Russell 2000 ETF (VTWO) has entered 2026 with renewed technical strength, breaking through several key indicators that suggest a potential trend reversal. On January 2, 2026, VTWO’s Momentum Indicator moved decisively above zero, a signal often associated with the early stages of bullish cycles. This followed an earlier technical milestone in December 2025, when the 10-day moving average crossed above the 50-day, drawing attention from momentum and swing traders alike.
CAOS, the trading ticker for IRIS Energy Limited, is emerging as a standout performer in early 2026 as two powerful trends converge: Bitcoin’s renewed surge and explosive demand for AI-ready data infrastructure. As Bitcoin pushes higher and investors hunt for leveraged exposure to both crypto and artificial intelligence, CAOS has attracted increasing attention from retail and quantitative traders alike.